Displaying 37 - 48 of 275
Liver Tumours
6

Bayer: Evolving horizons in HCC diagnosis and therapy - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
6

AstraZeneca: Evolution Of HCC Management: Clinical Considerations For Mdt-Directed Care And Treatment Selection - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Liver Tumours
4

Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024

View
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Unlocking the genetic architecture of Steatotic Liver Disease. A new paradigm in patient management (Complete Session) - EASL Congress 2024

View
Metabolism, Alcohol & Toxicity
1

GSK: Meet the Experts - Genetic architecture of Steatotic Liver Disease (Complete Session) - EASL Congress 2024

View
Viral Hepatitis
1

GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024

View
Displaying 37 - 48 of 275